Biogen Financials

BIIB Stock  USD 228.33  3.31  1.47%   
Based on the analysis of Biogen's profitability, liquidity, and operating efficiency, Biogen Inc is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in August. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Short and Long Term Debt Total is expected to grow to about 7.7 B, whereas Cash is forecasted to decline to about 723.1 M. Key indicators impacting Biogen's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.520.4958
Sufficiently Up
Slightly volatile
Current Ratio1.91.9973
Notably Down
Slightly volatile
Investors should never underestimate Biogen's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Biogen's cash flow, debt, and profitability to make informed and accurate decisions about investing in Biogen Inc.

Net Income

1.17 Billion

  
Understanding current and past Biogen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biogen's financial statements are interrelated, with each one affecting the others. For example, an increase in Biogen's assets may result in an increase in income on the income statement.

Biogen Earnings Geography

The data published in Biogen's official financial statements typically reflect Biogen's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Biogen's quantitative information. For example, before you start analyzing numbers published by Biogen accountants, it's essential to understand Biogen's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the presentation of Biogen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biogen's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biogen's management manipulating its earnings.

Biogen Stock Summary

Biogen competes with Bristol Myers, AbbVie, Merck, Gilead Sciences, and Johnson Johnson. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 9610 people.
Foreign Associate
  Mexico
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS09062X1037
CUSIP09062X103 449370105
LocationMassachusetts; U.S.A
Business Address225 Binney Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.biogen.com
Phone617 679 2000
CurrencyUSD - US Dollar

Biogen Key Financial Ratios

Biogen's financial ratios allow both analysts and investors to convert raw data from Biogen's financial statements into concise, actionable information that can be used to evaluate the performance of Biogen over time and compare it to other companies across industries.

Biogen Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets27.2B24.6B23.9B24.6B26.8B28.2B
Other Current Liab3.4B3.3B3.3B2.8B838.4M969.8M
Net Debt3.5B6.5B5.3B3.2B6.3B6.6B
Retained Earnings16.5B14.0B13.9B16.5B17.6B18.5B
Cash2.9B1.3B2.3B3.4B1.0B723.1M
Net Receivables1.9B1.9B1.5B2.1B2.1B2.2B
Other Current Assets1.2B1.3B1.2B1.4B1.2B1.2B
Total Liab13.9B13.9B12.9B11.2B12.0B12.6B
Total Current Assets8.4B6.9B7.9B9.8B6.9B7.2B
Intangible Assets3.5B3.1B2.2B1.9B8.4B8.8B
Accounts Payable530.8M454.9M589.2M491.5M403.3M423.5M
Inventory804.2M1.1B1.4B1.3B2.5B2.7B
Other Liab4.2B2.4B2.0B1.3B1.5B969.6M
Other Assets3.2B4.2B3.4B1.7B1.9B2.0B
Long Term Debt4.5B7.4B6.3B6.3B6.8B7.1B
Good Will5.8B5.8B5.8B5.7B6.2B3.2B
Net Tangible Assets4.1B1.9B2.9B5.8B6.7B4.1B

Biogen Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense187.4M222.5M253.6M246.6M246.9M259.2M
Total Revenue14.4B13.4B11.0B10.2B9.8B10.3B
Gross Profit12.4B11.6B8.9B7.9B7.3B3.9B
Operating Income7.0B4.6B2.8B2.3B1.3B1.6B
Ebit7.0B4.6B2.8B2.3B2.1B1.7B
Ebitda7.5B4.8B3.7B2.7B2.6B1.9B
Cost Of Revenue2.0B1.8B2.1B2.3B2.5B2.7B
Income Before Tax7.1B5.0B1.7B3.6B1.3B1.6B
Net Income5.9B4.0B1.6B3.0B1.2B1.2B
Income Tax Expense1.2B992.3M52.5M632.8M135.3M128.5M
Research Development2.3B4.0B2.5B2.2B2.5B1.4B
Minority Interest(4.1M)59.9M171.5M85.3M(400K)(380K)
Non Recurring1.5M75M18M131.1M118.0M99.1M
Tax Provision1.2B992.3M52.5M632.8M135.3M128.5M
Interest Income120M42M11M89.3M276.5M290.3M
Net Interest Income(67.4M)(180.5M)(242.6M)(157.3M)29.6M31.1M

Biogen Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash1.7B(1.6B)930.2M1.2B(2.4B)(2.3B)
Free Cash Flow6.4B3.7B3.3B1.1B1.2B1.3B
Depreciation680.6M457.2M487.7M518.4M494.8M348.0M
Other Non Cash Items60.8M(448M)1.8B(1.3B)581.2M610.3M
Dividends Paid302.7M36.4M4.6M700K805K764.8K
Capital Expenditures669.5M551.8M294.9M243.2M311.4M429.3M
Net Income5.9B4.1B1.7B3.0B1.2B1.3B
End Period Cash Flow2.9B1.3B2.3B3.4B1.0B800.3M
Change To Inventory(19.2M)(316.3M)(462.4M)(320.2M)(130.9M)(137.4M)
Investments1.2B(29.9M)(309.8M)1.6B(4.1B)(3.9B)
Change Receivables68.8M2.8M324.8M(203.4M)(233.9M)(245.6M)
Change To Netincome254.9M673.6M743.3M(1.5B)(1.3B)(1.3B)

Biogen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biogen's current stock value. Our valuation model uses many indicators to compare Biogen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biogen competition to find correlations between indicators driving Biogen's intrinsic value. More Info.
Biogen Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about  0.60  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biogen Inc is roughly  1.66 . At present, Biogen's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biogen's earnings, one of the primary drivers of an investment's value.

Biogen's Earnings Breakdown by Geography

Biogen Inc Systematic Risk

Biogen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biogen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Biogen Inc correlated with the market. If Beta is less than 0 Biogen generally moves in the opposite direction as compared to the market. If Biogen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biogen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biogen is generally in the same direction as the market. If Beta > 1 Biogen moves generally in the same direction as, but more than the movement of the benchmark.

Biogen Thematic Clasifications

Biogen Inc is part of Hedge Favorites investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Investment assets that are popular or favored by hedge funds. Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques.
Hedge FavoritesView
This theme covers Investment assets that are popular or favored by hedge funds. Hedge Funds pool capital from accredited individuals or institutional investors and invest in a variety of assets, often with complex portfolio-construction and risk-management techniques. . Get More Thematic Ideas
Today, most investors in Biogen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biogen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biogen growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.5)

At present, Biogen's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Biogen July 17, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Biogen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biogen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biogen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Biogen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biogen's daily price indicators and compare them against related drivers.

Complementary Tools for Biogen Stock analysis

When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years